MRI characteristics predict the efficacy of meloxicam treatment in patients with desmoid-type fibromatosis

被引:4
作者
Shimizu, Koki [1 ]
Hamada, Shunsuke [2 ]
Sakai, Tomohisa [3 ]
Ito, Shinji [4 ]
Urakawa, Hiroshi [3 ,5 ]
Arai, Eisuke [3 ]
Ikuta, Kunihiro [3 ]
Koike, Hiroshi [3 ]
Ishiguro, Naoki [3 ]
Nishida, Yoshihiro [3 ,6 ]
机构
[1] Tonokosei Hosp, Dept Orthoped Surg, Mizunami, Gifu, Japan
[2] Aichi Canc Ctr Hosp, Dept Orthoped Surg, Nagoya, Aichi, Japan
[3] Nagoya Univ, Grad Sch Med, Dept Orthoped Surg, Nagoya, Aichi, Japan
[4] Nagoya Univ, Grad Sch Med, Dept Radiol, Nagoya, Aichi, Japan
[5] Nagoya Univ Hosp, Dept Clin Oncol & Chemotherapy, Nagoya, Aichi, Japan
[6] Nagoya Univ Hosp, Dept Rehabil Med, Nagoya, Aichi, Japan
关键词
desmoid-type fibromatosis; efficacy; meloxicam; MRI; predictor; AGGRESSIVE FIBROMATOSIS; PROGNOSTIC-FACTORS; RADIATION-THERAPY; SEE POLICY; TUMORS; CYCLOOXYGENASE-2; SURGERY; RECURRENCE; EXTREMITY; MUTATION;
D O I
10.1111/1754-9485.12940
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction This study aimed to determine the clinical significance of MRI characteristics as a possible predictor of responsiveness to meloxicam treatment in patients with desmoid-type fibromatosis (DF). Additionally, it analysed the correlation between CTNNB1 mutation status and signal intensity of MRI. Methods Forty-six patients consecutively treated with meloxicam composed this study. The low-intensity area (LIA) on T2-weighted MRI was determined. We divided patients into two groups based on the efficacy of meloxicam: a clinical benefit group (CB group, including CR: complete response; PR: partial response; and SD: stable disease) and non-clinical benefit group (NB group, including PD: progressive disease). Correlations of the efficacy with LIA and CTNNB1 mutation status with LIA were investigated. Results In total, 11, 17 and 18 patients showed PR, SD and PD, respectively. The mean LIA ratio before treatment was significantly higher (P < 0.001) in the CB group than in the NB group. For predicting the efficacy, sensitivity was 68%, and specificity was 89% when setting the cut-off value as 20% for LIA. Mean changes in the LIA ratio before and after treatment were significantly higher (P = 0.01) in the CB group than in the NB group. Mean LIA ratio before treatment was significantly lower (P < 0.001) in the S45F mutation group than in the other mutation group. In multivariate analysis, the LIA ratio before treatment was a significant predictor of responsiveness (P = 0.02). Conclusions MRI characteristics were a useful predictor of the efficacy of meloxicam in DF patients. It may be possible to predict the clinical outcome more accurately when combined with other factors, such as CTNNB1 mutantion status.
引用
收藏
页码:751 / 757
页数:7
相关论文
共 37 条
  • [1] Desmoid tumor: Prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy
    Ballo, MT
    Zagars, GK
    Pollack, A
    Pisters, PWT
    Pollock, RA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 158 - 167
  • [2] Role of Imaging in Management of Desmoid-type Fibromatosis: A Primer for Radiologists
    Braschi-Amirfarzan, Marta
    Keraliya, Abhishek R.
    Krajewski, Katherine M.
    Tirumani, Sree Harsha
    Shinagare, Atul B.
    Hornick, Jason L.
    Baldini, Elizabeth H.
    George, Suzanne
    Ramaiya, Nikhil H.
    Jagannathan, Jyothi P.
    [J]. RADIOGRAPHICS, 2016, 36 (03) : 767 - 782
  • [3] Wait-and-See Policy as a First-Line Management for Extra-Abdominal Desmoid Tumors
    Briand, Sylvain
    Barbier, Olivier
    Biau, David
    Bertrand-Vasseur, Axelle
    Larousserie, Frederique
    Anract, Philippe
    Gouin, Francois
    [J]. JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2014, 96A (08) : 631 - 638
  • [4] Can the MRI signal of aggressive fibromatosis be used to predict its behavior?
    Castellazzi, G.
    Vanel, D.
    Le Cesne, A.
    Le Pechoux, C.
    Caillet, H.
    Perona, F.
    Bonvalot, S.
    [J]. EUROPEAN JOURNAL OF RADIOLOGY, 2009, 69 (02) : 222 - 229
  • [5] CTNNB1 45F Mutation Is a Molecular Prognosticator of Increased Postoperative Primary Desmoid Tumor Recurrence An Independent, Multicenter Validation Study
    Colombo, Chiara
    Miceli, Rosalba
    Lazar, Alexander J.
    Perrone, Federica
    Pollock, Raphael E.
    Le Cesne, Axel
    Hartgrink, Henk H.
    Cleton-Jansen, Anne-Marie
    Domont, Julien
    Bovee, Judith V. M. G.
    Bonvalot, Sylvie
    Lev, Dina
    Gronchi, Alessandro
    [J]. CANCER, 2013, 119 (20) : 3696 - 3702
  • [6] 'Difficult to diagnose' desmoid tumours: a potential role for CTNNB1 mutational analysis
    Colombo, Chiara
    Bolshakov, Svetlana
    Hajibashi, Shohrae
    Lopez-Terrada, Lola
    Wang, Wei-Lien
    Rao, Priya
    Benjamin, Robert S.
    Lazar, Alexander J.
    Lev, Dina
    [J]. HISTOPATHOLOGY, 2011, 59 (02) : 336 - 340
  • [7] High frequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management
    Domont, J.
    Salas, S.
    Lacroix, L.
    Brouste, V.
    Saulnier, P.
    Terrier, P.
    Ranchere, D.
    Neuville, A.
    Leroux, A.
    Guillou, L.
    Sciot, R.
    Collin, F.
    Dufresne, A.
    Blay, J-Y
    Le Cesne, A.
    Coindre, J-M
    Bonvalot, S.
    Benard, J.
    [J]. BRITISH JOURNAL OF CANCER, 2010, 102 (06) : 1032 - 1036
  • [8] Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis
    Fiore, Marco
    Colombo, Chiara
    Radaelli, Stefano
    Callegaro, Dario
    Palassini, Elena
    Barisella, Marta
    Morosi, Carlo
    Baldi, Giacomo G.
    Stacchiotti, Silvia
    Casali, Paolo G.
    Gronchi, Alessandro
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 (18) : 2800 - 2807
  • [9] Desmoid-Type Fibromatosis: A Front-Line Conservative Approach to Select Patients for Surgical Treatment
    Fiore, Marco
    Rimareix, Francoise
    Mariani, Luigi
    Domont, Julien
    Collini, Paola
    Le Pechoux, Cecile
    Casali, Paolo G.
    Le Cesne, Axel
    Gronchi, Alessandro
    Bonvalot, Sylvie
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (09) : 2587 - 2593
  • [10] Fletcher C. D. M. B. J., 2013, WHO Classification of Tumours of Soft Tissue and Bone, V5